

**Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab)  
Recombinant Antibody  
Catalog # APR10369****Specification****Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) - Product Information**

|                   |                            |
|-------------------|----------------------------|
| Application       | FC, Kinetics, Animal Model |
| Primary Accession | <a href="#">P20701</a>     |
| Reactivity        | Human                      |
| Clonality         | Monoclonal                 |
| Isotype           | IgG1                       |
| Calculated MW     | 146.14 KDa                 |

**Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) - Additional Information****Target/Specificity**Integrin  $\alpha$ L / ITGAL / CD11a**Endotoxin**< 0.001EU/  $\mu$ g,determined by LAL method.**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) - Protein Information****Name** ITGAL ([HGNC:6148](#))**Synonyms** CD11A**Function**

Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R (PubMed:<a href="http://www.uniprot.org/citations/11812992" target="\_blank">11812992</a>, PubMed:<a href="http://www.uniprot.org/citations/15528364" target="\_blank">15528364</a>). Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:<a href="http://www.uniprot.org/citations/29100055" target="\_blank">29100055</a>). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity (PubMed:<a href="http://www.uniprot.org/citations/15356110"

target="\_blank">15356110</a>). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:<a href="http://www.uniprot.org/citations/11812992" target="\_blank">11812992</a>). Acts as a platform at the immunological synapse to translate TCR engagement and density of the ITGAL ligand ICAM1 into graded adhesion (PubMed:<a href="http://www.uniprot.org/citations/38195629" target="\_blank">38195629</a>). Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis (By similarity). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:<a href="http://www.uniprot.org/citations/23775590" target="\_blank">23775590</a>).

#### Cellular Location

Cell membrane; Single-pass type I membrane protein. Note=Upon antigen recognition by the TCR, is recruited to lipid rafts (PubMed:15684041).

#### Tissue Location


Leukocytes.

### Anti-Integrin $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-Integrin $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) - Images



Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Integrin  $\alpha$ L / ITGAL / CD11a Reference Antibody (efalizumab) is more than 98.77%, determined by SEC-HPLC.